Annual Results & Strategic Outlook
Biotalys Announces 2025 Financial Results and Strategic Pivot Toward Commercial Readiness
EPA Approval of EVOCA™ Validates AGROBODY™ Platform for Sustainable Crop Protection
Year-End Cash
€8.0 Million
Financial Runway
End of May 2026
Regulatory Status
U.S. EPA Approved
Biotalys (Euronext: BTLS) has announced its consolidated financial results for 2025, highlighting a major value inflection point with the U.S. EPA approval of EVOCA™, its first protein-based biocontrol. The company is currently implementing a strategic refocus to concentrate resources on high-priority commercial programs, aiming to materially reduce its cash burn until the end of 2028.
Strategic Refocus and Operational Streamlining
Following a post-period decision in early February 2026, Biotalys is proceeding with a streamlined operational model:
- Suspension of early-stage activities to reduce operating expenses while safeguarding the technology platform.
- Prioritization of lead biofungicide assets, EVOCA™ and BioFun-6, in high-value markets.
- Opening research programs BioFun-4 and BioFun-8 for R&D collaboration with third parties.
Pipeline and Regulatory Progress
The company’s product pipeline achieved several critical milestones throughout 2025 and early 2026:
- EVOCA™: Earned U.S. EPA approval in December 2025 and Florida state registration in April 2026. In Europe, the Dutch regulator (CTGB) has recommended approval throughout the EU.
- BioFun-6: Field trials demonstrated increased potency, matching EVOCA’s performance at significantly lower dosage rates.
- BioIns-2: Advanced in collaboration with Syngenta, reaching a first research milestone in April 2026.
- Intellectual Property: Expanded patent protection for EVOCA™ in China and Brazil, and obtained a U.S. patent for BioFun-6 active ingredients.
Financial and Partnership Highlights
Biotalys forged key partnerships to accelerate production and expand into post-harvest markets:
- 21st.BIO Partnership: Collaborating with the Danish precision fermentation leader to scale production at commercially competitive costs.
- AgroFresh Alliance: Developing sustainable solutions to reduce global food waste from fungal decay in post-harvest produce.
- Financing: While the current runway extends to May 2026, negotiations with investors regarding further financing options are well-advanced.
Leadership Transitions
The company has streamlined its leadership to guide this commercial phase:
- Carlo Boutton: Appointed as CEO ad interim in March 2026.
- Luc Van fraeyenhoven: Appointed as CFO in May 2025 to provide cost-conscious financial leadership.
- Audit Committee: Patrik Haesen appointed as Chair of the Audit Committee.
Biotalys – Agricultural Technology
Annual Report 2025 | Gent, Belgium | biotalys.com
Leave a Reply